Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet

Metabolism: Clinical and Experimental

Volumn 62, Issue 7, 2013, Pages 939-951

  Nakaya, Keizo ^a   Kubota, Naoto ^a,b,c   Takamoto, Iseki ^a   Kubota, Tetsuya ^a,c,d   Katsuyama, Hisayuki ^a   Sato, Hiroyuki ^a   Tokuyama, Kumpei ^e   Hashimoto, Shinji ^f   Goto, Moritaka ^f   Jomori, Takahito ^f   Ueki, Kohjiro ^a,b   Kadowaki, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^d TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

cell mass; DPP 4 inhibitor; GLP 1; OGTT; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOKINASE; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; UNCOUPLING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; EPIDIDYMIS FAT; FOOD INTAKE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HAPLOINSUFFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY INTAKE; GLUCAGON-LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSE INTOLERANCE; HAPLOINSUFFICIENCY; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; PYRIMIDINES; WEIGHT GAIN;

EID: 84879525948     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.01.010     Document Type: Article

References (35)

1. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
2. G.C. Weir, D.R. Laybutt, H. Kaneto, S. Bonner-Weir, and A. Sharma Beta-cell adaptation and decompensation during the progression of diabetes Diabetes 50 Suppl 1 2001 S154 S159
3. L.M. Dickson, and C.J. Rhodes Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am J Physiol Endocrinol Metab 287 2004 E192 E198
4. H. Sakuraba, H. Mizukami, N. Yagihashi, R. Wada, C. Hanyu, and S. Yagihashi Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients Diabetologia 45 2002 85 96
5. K.H. Yoon, S.H. Ko, J.H. Cho, J.M. Lee, Y.B. Ahn, and K.H. Song Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea J Clin Endocrinol Metab 88 2003 2300 2308
6. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
7. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur J Biochem 214 1993 829 835
8. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 80 1995 952 957
9. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
10. P. Froguel, H. Zouali, N. Vionnet, G. Velho, M. Vaxillaire, and F. Sun Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus N Engl J Med 328 1993 697 702
11. G. Velho, H. Blanche, M. Vaxillaire, C. Bellanne-Chantelot, V.C. Pardini, and J. Timsit Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families Diabetologia 40 1997 217 224
12. S. Del Guerra, R. Lupi, L. Marselli, M. Masini, M. Bugliani, and S. Sbrana Functional and molecular defects of pancreatic islets in human type 2 diabetes Diabetes 54 2005 727 735
13. C. Bouche, S. Serdy, C.R. Kahn, and A.B. Goldfine The cellular fate of glucose and its relevance in type 2 diabetes Endocr Rev 25 2004 807 830
14. Y. Terauchi, H. Sakura, K. Yasuda, K. Iwamoto, N. Takahashi, and K. Ito Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose J Biol Chem 270 1995 30253 30256
15. Y. Terauchi, I. Takamoto, N. Kubota, J. Matsui, R. Suzuki, and K. Komeda Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance J Clin Invest 117 2007 246 257
16. N. Kato, M. Oka, T. Murase, M. Yoshida, M. Sakairi, and S. Yamashita Discovery and pharmacological characterization of N-[2-({2-[(2S)-2- cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor Bioorg Med Chem 19 2011 7221 7227
17. C.F. Deacon, T.E. Hughes, and J.J. Holst Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig Diabetes 47 1998 764 769
18. N. Kubota, K. Tobe, Y. Terauchi, K. Eto, T. Yamauchi, and R. Suzuki Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia Diabetes 49 2000 1880 1889
19. N. Kubota, T. Kubota, S. Itoh, H. Kumagai, H. Kozono, and I. Takamoto Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding Cell Metab 8 2008 49 64
20. N. Kubota, Y. Terauchi, K. Tobe, W. Yano, R. Suzuki, and K. Ueki Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus J Clin Invest 114 2004 917 927
21. C.J. Rhodes Type 2 diabetes - a matter of beta-cell life and death? Science 307 2005 380 384
22. J. Shirakawa, K. Amo, H. Ohminami, K. Orime, Y. Togashi, and Y. Ito Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes J Biol Chem 286 2011 25467 25476
23. Q. Wang, and P.L. Brubaker Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice Diabetologia 45 2002 1263 1273
24. C. Tourrel, D. Bailbe, M. Lacorne, M.J. Meile, M. Kergoat, and B. Portha Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 51 2002 1443 1452
25. J. Mu, J. Woods, Y.P. Zhou, R.S. Roy, Z. Li, and E. Zycband Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes Diabetes 55 2006 1695 1704
26. Q. Cheng, P.K. Law, M. de Gasparo, and P.S. Leung Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo] acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)-[1,1′-biphenyl] -4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes J Pharmacol Exp Ther 327 2008 683 691
27. S. Park, X. Dong, T.L. Fisher, S. Dunn, A.K. Omer, and G. Weir Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function J Biol Chem 281 2006 1159 1168
28. U.S. Jhala, G. Canettieri, R.A. Screaton, R.N. Kulkarni, S. Krajewski, and J. Reed cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2 Genes Dev 17 2003 1575 1580
29. E. Gomez, C. Pritchard, and T.P. Herbert cAMP-dependent protein kinase and Ca2 + influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells J Biol Chem 277 2002 48146 48151
30. M.J. Kim, J.H. Kang, Y.G. Park, G.R. Ryu, S.H. Ko, and I.K. Jeong Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element J Endocrinol 188 2006 623 633
31. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice Eur J Pharmacol 588 2008 325 332
32. M. Prentki, and C.J. Nolan Islet beta cell failure in type 2 diabetes J Clin Invest 116 2006 1802 1812
33. B.R. Gedulin, S.E. Nikoulina, P.A. Smith, G. Gedulin, L.L. Nielsen, and A.D. Baron Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight Endocrinology 146 2005 2069 2076
34. M.A. Nauck Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 124 2011 S3 S18
35. R.A. DeFronzo, T. Okerson, P. Viswanathan, X. Guan, J.H. Holcombe, and L. MacConell Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study Curr Med Res Opin 24 2008 2943 2952 Technology Technology Technology Technology Technology